Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sertraline hydrochloride, quantity: 111.9 mg (equivalent: sertraline, qty 100 mg) - tablet, film coated - excipient ingredients: hyprolose; sodium starch glycollate type a; titanium dioxide; polysorbate 80; microcrystalline cellulose; calcium hydrogen phosphate; macrogol 400; hypromellose; magnesium stearate - children and adolescents sertraline hydrochloride is indicated for the treatment of children (aged 6 years of age and older) and adolescents with ocd.,adults sertraline hydrochloride is indicated for the treatment of: ? major depression, obsessive compulsive disorder (ocd) and panic disorder ? social phobia (social anxiety disorder) and the prevention of its relapse ? pre-menstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sertraline hydrochloride, quantity: 111.9 mg (equivalent: sertraline, qty 100 mg) - tablet, film coated - excipient ingredients: hyprolose; sodium starch glycollate type a; titanium dioxide; polysorbate 80; microcrystalline cellulose; calcium hydrogen phosphate; macrogol 400; hypromellose; magnesium stearate - children and adolescents sertraline hydrochloride is indicated for the treatment of children (aged 6 years of age and older) and adolescents with ocd.,adults sertraline hydrochloride is indicated for the treatment of: ? major depression, obsessive compulsive disorder (ocd) and panic disorder ? social phobia (social anxiety disorder) and the prevention of its relapse ? pre-menstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sertraline hydrochloride, quantity: 55.95 mg (equivalent: sertraline, qty 50 mg) - tablet, film coated - excipient ingredients: macrogol 400; titanium dioxide; microcrystalline cellulose; polysorbate 80; calcium hydrogen phosphate; magnesium stearate; sodium starch glycollate type a; hyprolose; hypromellose - children and adolescents sertraline hydrochloride is indicated for the treatment of children (aged 6 years of age and older) and adolescents with ocd.,adults sertraline hydrochloride is indicated for the treatment of: ? major depression, obsessive compulsive disorder (ocd) and panic disorder ? social phobia (social anxiety disorder) and the prevention of its relapse ? pre-menstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sertraline hydrochloride, quantity: 55.95 mg (equivalent: sertraline, qty 50 mg) - tablet, film coated - excipient ingredients: macrogol 400; titanium dioxide; microcrystalline cellulose; polysorbate 80; calcium hydrogen phosphate; magnesium stearate; sodium starch glycollate type a; hyprolose; hypromellose - children and adolescents sertraline hydrochloride is indicated for the treatment of children (aged 6 years of age and older) and adolescents with ocd.,adults sertraline hydrochloride is indicated for the treatment of: ? major depression, obsessive compulsive disorder (ocd) and panic disorder ? social phobia (social anxiety disorder) and the prevention of its relapse ? pre-menstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

luye pharma australia pty ltd - quetiapine fumarate, quantity: 460.5 mg (equivalent: quetiapine, qty 400 mg) - tablet, modified release - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium citrate dihydrate; hypromellose; magnesium stearate; macrogol 400; titanium dioxide - sequase xr is indicated for: bipolar disorder - maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes - treatment of depressive episodes associated with bipolar disorder (see dosage and administration) - treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate. efficacy of sequase xr in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine ir. schizophrenia: treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy. major depressive disorder: treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies. generalised anxiety disorder: treatment of generalised anxiety disorder (gad).

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

luye pharma australia pty ltd - quetiapine fumarate, quantity: 345.38 mg - tablet, modified release - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium citrate dihydrate; hypromellose; magnesium stearate; macrogol 400; titanium dioxide; iron oxide yellow - sequase xr is indicated for: bipolar disorder - maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes - treatment of depressive episodes associated with bipolar disorder (see dosage and administration) - treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate. efficacy of sequase xr in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine ir. schizophrenia: treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy. major depressive disorder: treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies. generalised anxiety disorder: treatment of generalised anxiety disorder (gad).

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

luye pharma australia pty ltd - quetiapine fumarate, quantity: 230.26 mg (equivalent: quetiapine, qty 200 mg) - tablet, modified release - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium citrate dihydrate; hypromellose; magnesium stearate; macrogol 400; titanium dioxide; iron oxide yellow - sequase xr is indicated for: bipolar disorder - maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes - treatment of depressive episodes associated with bipolar disorder (see dosage and administration) - treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate. efficacy of sequase xr in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine ir. schizophrenia: treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy. major depressive disorder: treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies. generalised anxiety disorder: treatment of generalised anxiety disorder (gad).

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

luye pharma australia pty ltd - quetiapine fumarate, quantity: 172.69 mg (equivalent: quetiapine, qty 150 mg) - tablet, modified release - excipient ingredients: microcrystalline cellulose; sodium citrate dihydrate; lactose monohydrate; hypromellose; titanium dioxide; magnesium stearate; macrogol 400 - sequase xr is indicated for: bipolar disorder - maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes - treatment of depressive episodes associated with bipolar disorder (see dosage and administration) - treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate. efficacy of sequase xr in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine ir. schizophrenia: treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy. major depressive disorder: treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies. generalised anxiety disorder: treatment of generalised anxiety disorder (gad).

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

luye pharma australia pty ltd - quetiapine fumarate, quantity: 57.56 mg (equivalent: quetiapine, qty 50 mg) - tablet, modified release - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium citrate dihydrate; hypromellose; magnesium stearate; macrogol 400; titanium dioxide; iron oxide yellow; iron oxide red - sequase xr is indicated for: bipolar disorder - maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes - treatment of depressive episodes associated with bipolar disorder (see dosage and administration) - treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate. efficacy of sequase xr in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine ir. schizophrenia: treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy. major depressive disorder: treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies. generalised anxiety disorder: treatment of generalised anxiety disorder (gad).

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - olanzapine, quantity: 5 mg - tablet, film coated - excipient ingredients: pectin; mannitol; isopropyl alcohol; hyprolose; purified talc; lactose monohydrate; purified water; triacetin; titanium dioxide; magnesium stearate; propylene glycol; butan-1-ol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - olanzapine is indicated for the treatment of schizophrenia and related psychoses.,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.